Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults
Yubo Zhang1, Jindi Li2, Shaohui Liu1
1Department of Occupational and Environmental Health, School of Public Health, Guangxi Medical University, Nanning 530021, China.
Background:
Individuals with hypertension have an elevated risk of dementia. The potential protective effects of dietary polyunsaturated fatty acids (PUFAs) against dementia remain unclear. In this study, we investigate associations between blood PUFA levels and dementia outcomes, while considering the genetic predisposition among hypertensive adults.
Methods:
We employed data from UK Biobank and a prospective cohort of 123,235 hypertensive participants aged 40-69 years were included for the analysis (2006-2022). Cox proportional hazards models adjusting for covariates were applied to assess the associations of blood levels of docosahexaenoic acid (DHA), N3FA, N6FA, linoleic acid (LA), total PUFA, and the N6FA/N3FA ratio with incident dementia, dementia mortality, and all-cause mortality. The analyses were also stratified by polygenic risk scores (PRS) or APOE genotypes.
Results:
Higher levels of DHA (HR 0.41, 95 % CI 0.27-0.62), N3FA, LA, N6FA, and total PUFA were associated with significantly reduced dementia incidence (P < 0.001). In contrast, a higher N6FA/N3FA ratio was linked to increased dementia risk. Similar trends were observed for mortality. APOE genotypes, rather than PRS, modified PUFA-dementia associations: individuals with low-to-moderate APOE risk showed greater protective effects of high PUFA levels compared to those with high-risk genotypes.
Conclusions:
Among hypertensive adults, higher PUFA levels are associated with reduced risks of dementia and mortality. An imbalanced N6FA/N3FA ratio increases risk, while APOE genotypes significantly modify PUFA-related dementia outcomes.
More Related Videos
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Related Concept Videos
Atherosclerosis III: Management
Dementia
The progression of dementia is generally gradual....
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Hypertension II: Pathophysiology
Coronary Artery Disease I: Introduction
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
